Tuojie Biotech (Shanghai) Co. Ltd. has prepared oxygen-containing fused tricyclic derivatives acting as CDK2/cyclin E1 and/or CDK4/cyclin D1 inhibitors. As such, they are reported to be potentially useful for the treatment of cancer, infections, autoimmune disease and inflammatory disorders.
Bioray Pharmaceutical Co. Ltd. has announced clinical trial clearance in China by the National Medical Products Administration (NMPA) for BR-111 for injection for the treatment of ROR1-positive hematological malignancies and solid tumors.
Xaicure Pharmaceuticals (Suzhou) Co. Ltd. has described histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) and/or histone acetyltransferase KAT6B (MOZ2; MYST-4) inhibitors reported to be useful for the treatment of cancer.
Mindrank AI Co. Ltd. and Mindrank Therapeutics (Suzhou) New Drug Research & Development Co. Ltd. have identified molecular glue degraders comprising cereblon (CRBN) ligands acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers reported to be useful for the treatment of cancer.
Pharmaengine Inc. and Sentinel Oncology Ltd. have synthesized Wee1-like protein kinase (Wee1) inhibitors and proteolysis targeting chimera (PROTAC) compounds reported to be useful for the treatment of cancer.
Hanyang University and Korea Institute of Science and Technology have disclosed HER2 (erbB2) inhibitors reported to be useful for the treatment of cancer.
Cyclin-dependent kinases 4 and 6 (CDK4/6) are crucial cell cycle regulators and have become significant targets in breast cancer therapy. Current CDK4/6 inhibitors, while effective, often come with adverse effects and resistance issues.
Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid leukemia (AML), which is associated with an increased risk of relapse. The presence of LSCs predicts treatment success and, therefore, eliminating LSCs has been proposed as a promising strategy to avoid relapses.
Tumor immune evasion mechanisms could be reversed by activating intracellular antiviral immune responses. It has been reported that the use of DNA methyltransferase (DNMT) inhibitors combined with poly(ADP ribose) polymerase (PARP) inhibitors activated stimulator of interferon genes (STING) signaling pathway in a process named pathogen mimicry response.
Melanoma is the most aggressive form of skin cancer and often spreads to the brain. Though immunotherapy has greatly improved the outlook for even metastatic melanoma patients, once melanoma brain metastases (MBM) develop, prognosis worsens, and available therapeutic options decline. Scientists at the Institute for Neurosciences (IN), a joint center of the Spanish National Research Council (CSIC) and the Miguel Hernández University of Elche (UMH) have found a way to tackle MBM through microglial reprogramming.
RSS
